Iranian Journal of Medical Sciences

Methionine Adenosyltransferase II Alpha Upregulation Correlates with Plasma Chitotriosidase Activity in Helicobacter pylori-Negative Gastric Cancer: A Hypothesis-Generating Pilot Study of a Candidate Tissue Biomarker

Document Type : Original Article(s)

Authors

1 Department of Clinical Biochemistry, Medical School, Kermanshah University of Medical Sciences, Kermanshah, Iran

2 Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

3 Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

10.30476/ijms.2026.110866.4671
Abstract
Background: Gastric cancer (GC) remains a major global health threat. Chronic inflammation is a key driver of gastric carcinogenesis, influencing both the tumor microenvironment and cellular metabolism. This study aimed to evaluate Methionine Adenosyltransferase II Alpha (MAT2A) and Chitotriosidase (CHIT1) expression in H. pylori-negative GC, assess MAT2A as a biomarker, and explore correlations with plasma CHIT1 activity and clinical features.
Methods: In this hypothesis-generating pilot case-control study conducted in Kermanshah (September 2024 to July 2025), 27 tumor tissues and 27 matched adjacent noncancerous tissues from GC patients were analyzed for expression of MAT2A and CHIT1 using qRT-PCR. Helicobacter pylori-positive patients were excluded from the study. For CHIT1 activity, plasma samples were obtained from the same 27 GC patients and 32 healthy control individuals. CHIT1 activity was assessed by a fluorometric method. Paired t test, independent t test, and Pearson’s test were used.
Results: MAT2A was significantly upregulated in tumor tissues compared to matched adjacent noncancerous tissue (fold change=3.863, P<0.001). The Area under the curve (AUC) for MAT2A expression was 0.848, with a sensitivity of 74.1% and specificity of 81.5% at the optimal cut-off value of 7.78 (AUC=0.848±0.05, 95% CI=0.7472-0.9497). The CHIT1 expression (fold change=1.347, P=0.221) and activity in the patient group (106.67±48.33 nmol/mL/h) compared to the healthy control (92.16±34.01 nmol/mL/h) (P=0.183) showed no significant differences between groups. Significant positive correlations were found between CHIT1 activity and the expression of both MAT2A (r=0.32, P=0.042) and CHIT1 (r=0.30, P=0.048).
Conclusion: Our results showed that MAT2A can act as a candidate tissue biomarker in gastric carcinogenesis. A weak but significant positive correlation was found between MAT2A expression and CHIT1 activity, suggesting a possible link between tumor metabolism and systemic macrophage activation. Therefore, selective targeting of the MAT2A pathway may be a promising approach for GC treatment. However, further functional and mechanistic studies are required to validate this therapeutic potential.

Highlights

Fatemeh Babajani (Google Scholar)
Hadi Mozafari (Google Scholar)

Keywords


1.     Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-49. doi: 10.3322/caac.21660. PubMed PMID: 33538338.
2.     Jaroenlapnopparat A, Bhatia K, Coban S. Inflammation and Gastric Cancer. Diseases. 2022;10. doi: 10.3390/diseases10030035. PubMed PMID: 35892729; PubMed Central PMCID: PMC9326573.
3.     Gou YK, Zhou J, Liu P, Wang MY. Research progress on monocyte/macrophage in the development of gastric cancer. Future Oncol. 2025;21:1939-49. doi: 10.1080/14796694.2025.2504334. PubMed PMID: 40351251; PubMed Central PMCID: PMC12153212.
4.     Guo J, Yang Y, Buettner R, Rosen ST. Targeting the methionine-methionine adenosyl transferase 2A- S -adenosyl methionine axis for cancer therapy. Curr Opin Oncol. 2022;34:546-51. doi: 10.1097/CCO.0000000000000870. PubMed PMID: 35788128; PubMed Central PMCID: PMC9365249.
5.     Yang C, Ou Y, Zhou Q, Liang Y, Li W, Chen Y, et al. Methionine orchestrates the metabolism vulnerability in cisplatin resistant bladder cancer microenvironment. Cell Death Dis. 2023;14:525. doi: 10.1038/s41419-023-06050-1. PubMed PMID: 37582769; PubMed Central PMCID: PMC10427658.
6.     Secker KA, Bloechl B, Keppeler H, Duerr-Stoerzer S, Schmid H, Schneidawind D, et al. MAT2A as Key Regulator and Therapeutic Target in MLLr Leukemogenesis. Cancers (Basel). 2020;12. doi: 10.3390/cancers12051342. PubMed PMID: 32456310; PubMed Central PMCID: PMC7281730.
7.     Lou Z, Zeng X, Zhao F, Zhang L, Weinshilboum RM, Tao K. Targeting MTAP creates a therapeutic vulnerability to PARP inhibition in brain metastatic TNBC by disrupting MAT2A mediated methionine metabolism. Research Square. 2023. doi: 10.21203/rs.3.rs-3579438/v1.
8.     Sanderson SM, Gao X, Dai Z, Locasale JW. Methionine metabolism in health and cancer: a nexus of diet and precision medicine. Nat Rev Cancer. 2019;19:625-37. doi: 10.1038/s41568-019-0187-8. PubMed PMID: 31515518.
9.     Murin R, Vidomanova E, Kowtharapu BS, Hatok J, Dobrota D. Role of S-adenosylmethionine cycle in carcinogenesis. Gen Physiol Biophys. 2017;36:513-20. doi: 10.4149/gpb_2017031. PubMed PMID: 29372684.
10.  Ma M, Kong P, Huang Y, Wang J, Liu X, Hu Y, et al. Activation of MAT2A-ACSL3 pathway protects cells from ferroptosis in gastric cancer. Free Radic Biol Med. 2022;181:288-99. doi: 10.1016/j.freeradbiomed.2022.02.015. PubMed PMID: 35182729.
11.  Di Francesco AM, Verrecchia E, Manna S, Urbani A, Manna R. The chitinases as biomarkers in immune-mediate diseases. Clin Chem Lab Med. 2023;61:1363-81. doi: 10.1515/cclm-2022-0767. PubMed PMID: 36473071.
12.  Zhang S, Chen Q, Guo ZB, Wan R. Expression and methionine adenosyltransferase 2A in gastric cancer and its clinical significance. Chin J Gen Surg. 2014;23:1711-3.
13.  Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 1994;93:1288-92. doi: 10.1172/JCI117084. PubMed PMID: 8132768; PubMed Central PMCID: PMC294082.
14.  Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017;19:649-58. doi: 10.1016/j.neo.2017.05.002. PubMed PMID: 28732212; PubMed Central PMCID: PMC5516091.
15.  Yang PW, Jiao JY, Chen Z, Zhu XY, Cheng CS. Keep a watchful eye on methionine adenosyltransferases, novel therapeutic opportunities for hepatobiliary and pancreatic tumours. Biochim Biophys Acta Rev Cancer. 2022;1877:188793. doi: 10.1016/j.bbcan.2022.188793. PubMed PMID: 36089205.
16.  Tellai AD, Haghnejad V, Antoine J, Khemiri Merouani B, Bronowicki JP, Dreumont N. The complex post-transcriptional regulation of genes coding for methionine adenosyl transferase: New insights for liver cancer. Biochimie. 2025;238:19-28. doi: 10.1016/j.biochi.2025.05.001. PubMed PMID: 40348354.
17.  Pulous FE, Steurer B, Pun FW, Zhang M, Ren F, Zhavoronkov A. MAT2A inhibition combats metabolic and transcriptional reprogramming in cancer. Drug Discov Today. 2024;29:104189. doi: 10.1016/j.drudis.2024.104189. PubMed PMID: 39306235.
18.  Cacciatore A, Shinde D, Musumeci C, Sandrini G, Guarrera L, Albino D, et al. Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancer. Nat Commun. 2024;15:6672. doi: 10.1038/s41467-024-50908-7. PubMed PMID: 39107274; PubMed Central PMCID: PMC11303763.
19.  Zhao C, Bu X. Promoter methylation of tumor-related genes in gastric carcinogenesis. Histol Histopathol. 2012;27:1271-82. doi: 10.14670/hh-27.1271. PubMed PMID: 22936446.
20.  Lee SY, Lee CM, Ma B, Kamle S, Elias JA, Zhou Y, et al. Targeting Chitinase 1 and Chitinase 3-Like 1 as Novel Therapeutic Strategy of Pulmonary Fibrosis. Front Pharmacol. 2022;13:826471. doi: 10.3389/fphar.2022.826471. PubMed PMID: 35370755; PubMed Central PMCID: PMC8969576.
21.  Nechita VI, Hajjar NA, Drugan C, Catana CS, Mois E, Nechita MA, et al. Chitotriosidase and Neopterin as Two Novel Potential Biomarkers for Advanced Stage and Survival Prediction in Gastric Cancer-A Pilot Study. Diagnostics (Basel). 2023;13. doi: 10.3390/diagnostics13071362. PubMed PMID: 37046579; PubMed Central PMCID: PMC10093230.
22.  Dong Z, Kumar R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell. 1997;88:801-10. doi: 10.1016/s0092-8674(00)81926-1. PubMed PMID: 9118223.
23.  Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20:28. doi: 10.1186/s12943-021-01316-8. PubMed PMID: 33546704; PubMed Central PMCID: PMC7863491.
24.  Hobson-Gutierrez SA, Carmona-Fontaine C. The metabolic axis of macrophage and immune cell polarization. Dis Model Mech. 2018;11. doi: 10.1242/dmm.034462. PubMed PMID: 29991530; PubMed Central PMCID: PMC6124558.
25.   Yu W, Wang Z, Zhang K, Chi Z, Xu T, Jiang D, et al. One-Carbon Metabolism Supports S-Adenosylmethionine and Histone Methylation to Drive Inflammatory Macrophages. Mol Cell. 2019;75:1147-60. doi: 10.1016/j.molcel.2019.06.039. PubMed PMID: 31420217.

Articles InPress, Corrected Proof
Available Online from 16 November 2026


  • Received 23 February 2026
  • Revised 01 June 2026
  • Accepted 03 July 2026